Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 11 May 2010
Vol. 3, Issue 121, p. ec141
[DOI: 10.1126/scisignal.3121ec141]

EDITORS' CHOICE

Immunology Tolerating Tumors

Kristen L. Mueller

Science, AAAS, Washington, DC 20005, USA

Successful tumor growth depends on the ability of the tumor to escape detection by the immune system. Human cancers that express the chemokine receptor CCR7 are associated with tumor metastasis and poor prognosis, suggesting that CCR7-dependent signaling might lead to an immunotolerant tumor microenvironment. Shields et al. (see the Perspective by Zindl and Chaplin) studied a mouse melanoma model in which the tumors expressed varying amounts of the CCR7 ligand, CCL21. Tumors expressing CCL21 exhibited more aggressive growth and attracted a class of suppressive, rather than proinflammatory, leukocytes. Furthermore, the tumor microenvironment was rich in immunosuppressive cytokines and exhibited lymph node–like features. These features were not present in tumors that expressed low amounts of CCL21. Thus, tumor CCL21 expression promotes an immunotolerant tumor microenvironment, which is permissive for tumor growth and spread.

J. D. Shields, I. C. Kourtis, A. A. Tomei, J. M. Roberts, M. A. Swartz, Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749–752 (2010). [Abstract] [Full Text]

C. L. Zindl, D. D. Chaplin, Tumor immune evasion. Science 328, 697–698 (2010). [Summary] [Full Text]

Citation: K. L. Mueller, Tolerating Tumors. Sci. Signal. 3, ec141 (2010).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882